A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs TSR 042 (Primary)
- Indications Endometrial cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Acronyms GARNET
- Sponsors TESARO
- 09 Aug 2017 According to a TESARO Inc. media release, data from this trial are expected to be presented at the European Society for Medical Oncology (ESMO) Congress 2017.
- 13 Jul 2017 Planned number of patients changed from 379 to 435.
- 13 Jul 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History